<meta name="summary-card" content="false">
<div class="table-container">
<table class="table1" id="HemeOnc">
<thead>
<tr>
<th colspan="5" class="table-title">
<strong>Heme-Onc Gene Mutations Summary</strong>
</th>
</tr>
<tr>
<th class="soft-header">Disease</th>
<th class="soft-header">Gene / Mutation</th>
<th class="soft-header">Cytogenetics</th>
<th class="soft-header">Mechanism</th>
<th class="soft-header">Lineage</th>
</tr>
</thead>
<tbody>
<tr><td>Chronic Myeloid Leukemia (CML)</td><td>BCR-ABL fusion</td><td>t(9;22), Philadelphia chromosome</td><td>Oncogene activation</td><td >Myeloid</td></tr>
<tr><td>Acute Promyelocytic Leukemia (APL)</td><td>PML-RARA fusion</td><td>t(15;17)</td><td>Oncogene activation</td><td >Myeloid</td></tr>
<tr><td>Burkitt Lymphoma</td><td>MYC translocation</td><td>t(8;14)</td><td>Oncogene activation</td><td >Lymphoid</td></tr>
<tr><td>Mantle Cell Lymphoma</td><td>Cyclin D1 (CCND1) translocation</td><td>t(11;14)</td><td>Oncogene activation</td><td >Lymphoid</td></tr>
<tr><td>Follicular Lymphoma</td><td>BCL2 translocation</td><td>t(14;18)</td><td>Apoptosis inhibition</td><td >Lymphoid</td></tr>
<tr><td>Diffuse Large B-Cell Lymphoma</td><td>BCL6 mutations</td><td>various</td><td>Oncogene activation</td><td >Lymphoid</td></tr>
<tr><td>Hairy Cell Leukemia</td><td>BRAF V600E mutation</td><td>point mutation</td><td>MAPK pathway activation</td><td >Other</td></tr>
<tr><td>Acute Lymphoblastic Leukemia (ALL)</td><td>TEL-AML1, BCR-ABL</td><td>various</td><td>Fusion oncogenes</td><td >Lymphoid</td></tr>
<tr><td>T-ALL</td><td>NOTCH1 gain-of-function</td><td>point mutation</td><td>T-cell proliferation</td><td >Lymphoid</td></tr>
<tr><td>Chronic Lymphocytic Leukemia (CLL)</td><td>Deletion 13q14</td><td>del(13q)</td><td>Tumor suppressor loss</td><td >Lymphoid</td></tr>
<tr><td>Multiple Myeloma</td><td>Deletion 17p (TP53)</td><td>del(17p)</td><td>Tumor suppressor loss</td><td >Other</td></tr>
<tr><td>Myelodysplastic Syndromes (MDS)</td><td>Deletion 5q</td><td>del(5q)</td><td>Tumor suppressor loss</td><td >Myeloid</td></tr>
<tr><td>Polycythemia Vera</td><td><b>JAK2</b> V617F</td><td>point mutation</td><td>Tyrosine kinase activation</td><td >Myeloid</td></tr>
<tr><td>Essential Thrombocythemia</td><td><b>JAK2</b>, CALR, MPL</td><td>point mutations</td><td>Signal transduction</td><td >Myeloid</td></tr>
<tr><td>Primary Myelofibrosis</td><td><b>JAK2</b>, CALR, MPL</td><td>point mutations</td><td>Signal transduction</td><td >Myeloid</td></tr>
<tr><td>Hemochromatosis</td><td>HFE mutation</td><td>Chromosome 6p21.3</td><td>Iron overload disorder (non-oncogenic)</td><td >Other</td></tr>
<tr><td>Sickle Cell Disease</td><td>HBB gene mutation (Glu6Val)</td><td>Chromosome 11p15.5</td><td>Structural hemoglobinopathy</td><td >Other</td></tr>
<tr><td>Thalassemia (alpha)</td><td>HBA1, HBA2 deletions</td><td>Chromosome 16</td><td>Reduced alpha-globin synthesis</td><td >Other</td></tr>
<tr><td>Thalassemia (beta)</td><td>HBB point mutations</td><td>Chromosome 11</td><td>Reduced beta-globin synthesis</td><td >Other</td></tr>
<tr><td>G6PD Deficiency</td><td>G6PD mutation</td><td>Xq28</td><td>Enzymopathy – hemolytic anemia</td><td >Other</td></tr>
<tr><td>Hereditary Spherocytosis</td><td>ANK1, SPTB, SPTA1, EPB42</td><td>Various</td><td>Membrane defect (non-oncogenic)</td><td >Other</td></tr>
<tr><td>Fanconi Anemia</td><td>FANC genes</td><td>Various</td><td>DNA repair defect – pancytopenia, ↑ cancer risk</td><td >Other</td></tr>
</tr>
<tr>
  <td>Aplastic Anemia (Fanconi-Independent)</td>
  <td>TERT, TERC, DKC1</td>
  <td>Various</td>
  <td>Telomere maintenance failure → marrow failure</td>
  <td>Other</td>
</tr>
<tr>
  <td>Waldenström Macroglobulinemia</td>
  <td>MYD88 L265P mutation</td>
  <td>Point mutation</td>
  <td>NF-κB activation, excess IgM production</td>
  <td>Lymphoid</td>
</tr>
<tr>
  <td>Hemophilia A</td>
  <td>F8 gene mutation</td>
  <td>Xq28</td>
  <td>Factor VIII deficiency</td>
  <td>Other</td>
</tr>
<tr>
  <td>Hemophilia B</td>
  <td>F9 gene mutation</td>
  <td>Xq27.1–q27.2</td>
  <td>Factor IX deficiency</td>
  <td>Other</td>
</tr>
<tr>
  <td>Hemophilia C</td>
  <td>F11 gene mutation</td>
  <td>Chromosome 4q35</td>
  <td>Factor XI deficiency</td>
  <td>Other</td>
</tr>
<tr>
  <td>von Willebrand Disease</td>
  <td>VWF gene mutation</td>
  <td>12p13.31</td>
  <td>Defective platelet adhesion, low factor VIII</td>
  <td>Other</td>
</tr>
<tr>
  <td>Bernard-Soulier Syndrome</td>
  <td>GPIb gene mutation</td>
  <td>17p12</td>
  <td>Platelet adhesion defect</td>
  <td>Other</td>
</tr>
<tr>
  <td>Glanzmann Thrombasthenia</td>
  <td>ITGA2B, ITGB3 mutation</td>
  <td>17q21.32, 17q21.32</td>
  <td>Platelet aggregation defect (GPIIb/IIIa)</td>
  <td>Other</td>
</tr>
<tr>
  <td>Factor V Leiden</td>
  <td>F5 gene (Arg506Gln)</td>
  <td>1q24.2</td>
  <td>Resistance to activated protein C → thrombosis</td>
  <td>Other</td>
</tr>
<tr>
  <td>Prothrombin G20210A Mutation</td>
  <td>F2 gene</td>
  <td>11p11.2</td>
  <td>Increased prothrombin → thrombosis</td>
  <td>Other</td>
</tr>
<tr>
  <td>Antithrombin III Deficiency</td>
  <td>SERPINC1 gene</td>
  <td>1q25.1</td>
  <td>Increased thrombin activity → thrombosis</td>
  <td>Other</td>
</tr>
<tr>
  <td>Protein C Deficiency</td>
  <td>PROC gene mutation</td>
  <td>2q13–q14</td>
  <td>↓ inactivation of Va and VIIIa → thrombosis</td>
  <td>Other</td>
</tr>
<tr>
  <td>Protein S Deficiency</td>
  <td>PROS1 gene mutation</td>
  <td>3p11.1</td>
  <td>↓ cofactor for Protein C → thrombosis</td>
  <td>Other</td>
</tr>
</tbody>
</table>
</div>